Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Placebo-controlled risperidone discontinuation trial in people with intellectual disability
NL-OMON27969Phase 4Active, not recruiting
- Sponsor
- University Medical Center Groningen
- Start
- Jan 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in behavioral disorder and intellectual disability (ID) comparing Ongoing risperidone with Gradual discontinuation to placebo (2 arms). Primary endpoint: Aberrant Behaviour Checklist irritability subscale. Started Jan 2016; status: active, not recruiting.
02
Drugs
risperidone
03
Conditions
behavioral disorderintellectual disability (ID)
Beyond the preview
Go deeper on NL-OMON27969.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON27969.